From None: 2025-05-01 06:05:00

In a highly anticipated move, Eli Lilly is set to announce a substantial increase in earnings and revenue for the first quarter of 2025. Analysts predict earnings of $3.46 per share and revenue of $12.72 billion, showcasing the company’s impressive growth in the pharmaceutical sector.

The ACHIEVE-1 trial results for orforglipron have had a positive impact on Eli Lilly’s stock, with shares rising by 1.6% to $898.95. The trial demonstrated promising outcomes for type 2 diabetes patients, positioning orforglipron as a potential leader in oral obesity treatments.

Eli Lilly’s stock is currently showing a bullish trend, trading above key moving averages and indicating a positive outlook for long-term investors. The stock price of $898.95 reflects a 1.55% increase, with a trading range between $882.12 and $902.50.

Over the past year, Eli Lilly’s stock has seen a 14.35% increase in value, with a year-to-date increase of 14.79%. The company’s market capitalization stands at approximately $852.19 billion, with a trading volume of 3,154,448 shares on the NYSE.



Read more at None:: Eli Lilly and Company (NYSE:LLY) Earnings Preview …